Boston Biomedical

Boston Biomedical is a Cambridge, Massachusetts-based biotechnology company whose mission is to develop the next generation of targeted cancer therapeutics in order to fundamentally change cancer medicine for the benefit of cancer patients.

Boston Biomedical is recognized as an industry leader in the creation of novel compounds designed to target cancer stem cells (CSCs). CSCs are a sub-population of cancer cells that are highly malignant and are considered to be fundamentally responsible for cancer growth, recurrence, drug-resistance and metastasis. Moreover, CSCs are highly resistant to current chemotherapies and targeted agents. Targeting CSCs, therefore, holds great promise for fundamentally advancing cancer treatment.

Boston Biomedical was founded in 2006 by Dr. Chiang J. Li, MD FACP. In April, 2012, Sumitomo Dainippon Pharma of Osaka, Japan acquired Boston Biomedical. After the acquisition, Boston Biomedical became 100% owned by Sumitomo Dainippon Pharma and continued its operations in the Boston area. Boston Biomedical has developed a unique corporate culture and has full capability for oncology drug research and development including drug discovery, crystallography, medicinal chemistry, preclinical development, pharmacology, pharmaceutical development, global clinical trials and regulatory affairs. Moreover, Boston Biomedical scientists have established an extraordinary track record of accomplishments, including the discovery and development of over 10 discovery-stage oncology programs and 5 clinical-stage oncology programs including BBI608, a CSC inhibitor in Phase III trials in North America and Australasia; and BBI503, a CSC kinase inhibitor currently in Phase I trials in North America.

Boston Biomedical aims to continue to leverage its innovation-driven culture, scientific leadership and drug development expertise in order to advance the development of novel cancer therapeutics for patients suffering from cancer.

BBI608

BBI608 is the most clinically advanced candidate in Boston Biomedical’s cancer stem cell pathway program. This first-in-class, orally-administered small molecule blocks cancer stem cell (CSC) self-renewal and induces cell death in CSCs as well as non-stem cancer cells. Preclinically, BBI608 has shown broad-spectrum anti-tumor and anti-metastatic activity. BBI608 has demonstrated safety and encouraging signs of efficacy in early-phase clinical trials. Under a Special Protocol Agreement with US FDA, BBI608 has entered a Phase III randomized study in patients with pretreated advanced colorectal cancer. Multiple Phase Ib/II and Phase II clinical trials of BBI608 alone or in combination with other agents are also ongoing in a variety tumor types.

* Accrual of new patients has been stopped.
BBI503

BBI503 is the most advanced candidate in Boston Biomedical’s CSC kinase inhibitor program. BBI503 is a first-in-class, orally-administered, CSC kinase inhibitor that blocks CSC self-renewal and induces cell death in CSCs as well as non-stem cancer cells. BBI503 has shown potent anti-cancer activity against a broad range of tumor types in preclinical studies. BBI503 is currently in a multi-center Phase I clinical trial to evaluate safety in patients with advanced malignancies in North America.
Research Programs

Multiple programs aimed at targeting CSCs are currently in various stages of preclinical research and development.